Eesti - eesti - Ravimiamet

teva b.v. - domperidoon - tablett - 10mg 100tk; 10mg 20tk; 10mg 10tk; 10mg 30tk

Eesti - eesti - Ravimiamet

pierre fabre medicament - domperidoon - suus dispergeeruv tablett - 10mg 10tk; 10mg 21tk; 10mg 30tk

Eesti - eesti - Ravimiamet

jntl consumer health (france) sas - domperidoon - õhukese polümeerikattega tablett - 10mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunaviiri - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):ravi hiv-1 nakkuse retroviirusevastast ravi (art)-kogenud täiskasvanud patsientidele, sealhulgas neid, mis on väga eeltöödeldud. ravi hiv-1 nakkuse pediaatrilised patsiendid alates vanusest 3 aastat ja vähemalt 15 kg kehakaalu kohta. otsustades ravi alustada darunavir co-manustatakse koos väikeses annuses ritonaviiri, tuleks hoolikalt kaaluda ravi ajalugu konkreetse patsiendi ja mustreid mutatsioonid on seotud erinevate mõjurite. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 ja 5. darunavir co-manustatakse koos väikeses annuses ritonaviir on näidustatud kombinatsioonis teiste viirusevastase ravimitega ravi patsientidel, kellel on inimese immuunpuudulikkuse viiruse (hiv-1) nakkus.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. otsustades ravi alustada darunavir sellisel kunsti-kogenud patsientidel, genotypic katsetamine peaks juhendi kasutamine darunavir (vt lõigud 4. 2, 4. 3, 4. 4 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

otsuka novel products gmbh - delamanid - tuberkuloos, multidrug-resistentne - antimükobakterid - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 ja 5. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - darunaviiri - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international n.v. - telapreviir - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - incivo, koos peginterferon alfa ja ribavirin, on näidustatud ravi genotüüp-1 krooniline hepatiit c täiskasvanud patsientidel, kellel on kompenseeritud maksahaigus (sh tsirroos):kes on ravi naiivne, kes on varem ravitud interferoon alfa (pegylated või mitte-pegylated), üksi või koos ribavirin, sealhulgas relapsers, osaline ravile ja null ravile.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - hiv-nakkused - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta on näidustatud koos teiste retroviirusevastaste ravimitega inimese immuunpuudulikkuse viiruse 1 (hiv 1) nakkuse raviks 18-aastastel ja vanematel täiskasvanutel. genotypic katsetamine peaks juhendi kasutamine rezolsta.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutiniib (monohüdraadina) - leukeemia, müeloid - antineoplastic agents, protein kinase inhibitors - bosulif on näidustatud ravi täiskasvanud patsientidel, kellel on:äsja diagnoositud krooniline faas (lp) philadelphia kromosoom-positiivse kroonilise müeloidse leukeemia (ph+ cml). cp, kiirendatud etapp (ap), ja plahvatuse etapp (bp) ph+ cml eelnevalt ravitud ühe või mitme türosiinkinaasi inhibiitor(s) [tki(s)] ja kellele imatinib, nilotinib ja dasatinib ei ole asjakohane ravi valikud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

orion corporation - ropinirole vesinikkloriid - dopaminergic ained, dopamiini agonistid - koerad - induktsiooni oksendamine koertel.